Want to see TSE:PRN full AI Analyst Report?
PRN Stock Chart & Stats
C$7.63
C$0.04(0.36%)
At close: 4:00 PM EST
C$7.63
C$0.04(0.36%)
Day’s Range― - ―
52-Week RangeC$5.23 - C$12.40
Previous CloseN/A
Volume2.80K
Average Volume (3M)24.45K
Market Cap
C$342.66M
Enterprise ValueC$157.64M
Total Cash (Recent Filing)C$50.33M
Total Debt (Recent Filing)C$7.47M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Jul 30, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding36,337,640
10 Day Avg. Volume21,380
30 Day Avg. Volume24,453
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)3.58
Price to Sales (P/S)14.48
P/FCF Ratio-6.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$15.61Price Target Upside104.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.83
Revenue Forecast (FY)C$27.12M
Bulls Say, Bears Say
Bulls Say
Growth GuidanceProfound reported Q4 results mostly in line with expectations and guided to 70%-75% growth this year, with the opportunity to reach triple-digit growth rates next year and beyond.
Reimbursement RatesTULSA received a substantially higher reimbursement rate for 2025 from CMS than RARP, potentially making it more profitable for many institutions.
Tariff And Trade ComplianceProfound is almost certainly unlikely to face any challenges on tariff concerns as the company is USMCA compliant, allowing their products to be traded duty-free.
Bears Say
Market CompetitionProfound is bringing more attention to the BPH opportunity and addressed Procept BioRobotics’ Aquablation, highlighting TULSA's unique versatility.
Profound Medical News
PRN FAQ
What was Profound Medical’s price range in the past 12 months?
Profound Medical lowest stock price was C$5.23 and its highest was C$12.40 in the past 12 months.
What is Profound Medical’s market cap?
Profound Medical’s market cap is C$342.66M.
When is Profound Medical’s upcoming earnings report date?
Profound Medical’s upcoming earnings report date is Jul 30, 2026 which is in 28 days.
How were Profound Medical’s earnings last quarter?
Profound Medical released its earnings results on May 07, 2026. The company reported -C$0.27 earnings per share for the quarter, beating the consensus estimate of -C$0.355 by C$0.085.
Is Profound Medical overvalued?
According to Wall Street analysts Profound Medical’s price is currently Undervalued.
Does Profound Medical pay dividends?
Profound Medical does not currently pay dividends.
What is Profound Medical’s EPS estimate?
Profound Medical’s EPS estimate is -0.34.
How many shares outstanding does Profound Medical have?
Profound Medical has 36,337,640 shares outstanding.
What happened to Profound Medical’s price movement after its last earnings report?
Profound Medical reported an EPS of -C$0.27 in its last earnings report, beating expectations of -C$0.355. Following the earnings report the stock price went down -3.385%.
Which hedge fund is a major shareholder of Profound Medical?
Currently, no hedge funds are holding shares in TSE:PRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Profound Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.90%
12-Months-Change
Fundamentals
Return on Equity
-78.75%
Trailing 12-Months
Asset Growth
17.02%
Trailing 12-Months
Company Description
Profound Medical
Profound Medical Corp., along with its subsidiaries, operates as a commercial-stage medical technology firm. The company specializes in creating magnetic resonance (MR) guided ablation therapies designed to address prostate conditions, uterine fibroids, and to provide palliative pain management. Its market reach extends to Canada, Germany, the United States, and Finland. The company's primary offering is the TULSA-PRO system, which is engineered to integrate with magnetic resonance imaging (MRI) scanners within hospitals and clinical treatment facilities. Additionally, Profound Medical offers Sonalleve, a versatile therapeutic platform that treats uterine fibroids, delivers palliative pain relief for bone metastases, and provides non-invasive solutions for uterine fibroid treatment. Profound Medical Corp. maintains its corporate headquarters in Mississauga, Canada.
PRN Stock 12 Month Forecast
Average Price Target
C$15.61
▲(104.58% Upside)
Technical Analysis
Aurora Spine
―
Perimeter Medical Imaging AI
―
―
Theralase Technologies
―
VentriPoint Diagnostics
―
Options Prices
Currently, No data available
---








